Copyright
©The Author(s) 2020.
World J Psychiatr. Dec 19, 2020; 10(12): 286-298
Published online Dec 19, 2020. doi: 10.5498/wjp.v10.i12.286
Published online Dec 19, 2020. doi: 10.5498/wjp.v10.i12.286
Expression | Category | Term | Function | Count | P value |
Up-regulated | BP | GO: 0007399 | Nervous system development | 25 | 1.21E–08 |
BP | GO: 0007409 | Axonogenesis | 14 | 1.82E–08 | |
BP | GO: 0007268 | Chemical synaptic transmission | 16 | 1.33E–07 | |
BP | GO: 0030154 | Cell differentiation | 32 | 3.75E–06 | |
BP | GO: 0010976 | Positive regulation of neuron projection development | 12 | 1.51E–05 | |
CC | GO: 0045202 | Synapse | 43 | 1.25E–18 | |
CC | GO: 0043025 | Neuronal cell body | 39 | 1.18E–14 | |
CC | GO: 0030425 | Dendrite | 37 | 2.35E–14 | |
CC | GO: 0030054 | Cell junction | 44 | 7.70E–14 | |
CC | GO: 0030424 | Axon | 31 | 3.10E–13 | |
MF | GO: 0005515 | Protein binding | 99 | 3.15E–05 | |
MF | GO: 0050839 | Cell adhesion molecule binding | 8 | 1.71E–04 | |
MF | GO: 0019904 | Protein domain specific binding | 15 | 3.48E–04 | |
MF | GO: 0005216 | Ion channel activity | 11 | 5.51E–04 | |
MF | GO: 0008144 | Drug binding | 8 | 0.002625 | |
Down-regulated | BP | GO: 0015031 | Protein transport | 38 | 7.01E–06 |
BP | GO: 0007049 | Cell cycle | 38 | 1.59E–05 | |
BP | GO: 0016192 | Vesicle-mediated transport | 17 | 4.14E–04 | |
BP | GO: 0007040 | Lysosome organization | 7 | 7.61E–04 | |
BP | GO: 0006281 | DNA repair | 21 | 8.39E–04 | |
CC | GO: 0005737 | Cytoplasm | 243 | 1.19E–08 | |
CC | GO: 0005634 | Nucleus | 219 | 2.55E–07 | |
CC | GO: 0005829 | Cytosol | 77 | 5.42E–05 | |
CC | GO: 0005768 | Endosome | 30 | 4.60E–04 | |
CC | GO: 0005794 | Golgi apparatus | 53 | 4.91E–04 | |
MF | GO: 0046872 | Metal ion binding | 135 | 4.24E–06 | |
MF | GO: 0005515 | Protein binding | 156 | 1.17E–05 | |
MF | GO: 0003676 | Nucleic acid binding | 61 | 1.93E–05 | |
MF | GO: 0005487 | Nucleocytoplasmic transporter activity | 5 | 0.001069 | |
MF | GO: 0016874 | Ligase activity | 22 | 0.001335 |
Expression | Term | Definition | Count | P value |
Upregulated | mmu04080 | Neuroactive ligand-receptor interaction | 16 | 2.02E–05 |
mmu05014 | ALS | 6 | 1.08E–04 | |
mmu04530 | Tight junction | 8 | 1.23E–03 | |
mmu00430 | Taurine and hypotaurine metabolism | 2 | 1.30E–03 | |
mmu04020 | Calcium signaling pathway | 9 | 2.08E–03 | |
mmu00650 | Butanoate metabolism | 3 | 3.77E–03 | |
mmu04512 | ECM-receptor interaction | 5 | 6.91E–03 | |
mmu05322 | Systemic lupus erythematosus | 7 | 8.98E–03 | |
mmu04720 | Long-term potentiation | 4 | 1.25E–02 | |
mmu04010 | MAPK signaling pathway | 10 | 1.31E–02 | |
Downregulated | mmu05223 | Non-small cell lung cancer | 9 | 1.48E–05 |
mmu05212 | Pancreatic cancer | 10 | 2.35E–05 | |
mmu05160 | Hepatitis C | 14 | 4.31E–05 | |
mmu05211 | Renal cell carcinoma | 8 | 6.64E–04 | |
mmu05221 | Acute myeloid leukemia | 7 | 6.55E–04 | |
mmu04012 | ErbB signaling pathway | 9 | 6.19E–04 | |
mmu04620 | Toll-like receptor signaling pathway | 10 | 5.05E–04 | |
mmu03013 | RNA transport | 14 | 3.89E–04 | |
mmu05214 | Glioma | 8 | 3.55E–04 | |
mmu05215 | Prostate cancer | 10 | 1.91E–04 |
Term | Pathway | P value | Genes | |
Upregulated | Downregulated | |||
mmu04010 | MAPK signaling pathway | 1.51E–08 | Crkl, Fgf12, Mras, Mapt, Ntrk2, Dusp8, Ptpn5, Map3k4, Mapk8ip2, Dusp7 | Chuk, Egf, Egfr, Ikbkg, Kras, Nfkb1, Prkca, Pla2g4a, Sos1, Map3k8, Stk3, Tab2, Dusp16, Raf1, Taok1 |
mmu04014 | Ras signaling pathway | 1.84E–07 | Fgf12, Grin2b, Mras, Pgf, Ptpn11, Gng13 | Chuk, Egf, Egfr, Gab1, Ikbkg, Insr, Kras, Nfkb1, Pik3ca, Prkca, Pla2g4a, Sos1, Rassf5, Tbk1, Raf1, Rab5a |
mmu04012 | ErbB signaling pathway | 3.85E–06 | Camk2b, Cdkn1b, Crkl | Egf, Egfr, Gab1, Kras, Pik3ca, Prkca, Sos1, Tgfa, Raf1 |
- Citation: Bian YY, Yang LL, Zhang B, Li W, Li ZJ, Li WL, Zeng L. Identification of key genes involved in post-traumatic stress disorder: Evidence from bioinformatics analysis. World J Psychiatr 2020; 10(12): 286-298
- URL: https://www.wjgnet.com/2220-3206/full/v10/i12/286.htm
- DOI: https://dx.doi.org/10.5498/wjp.v10.i12.286